Evaluation of the toxicity and anti-angiogenic effects of beta-cyclodextrin complex loaded with thymol in melanoma skin cancer cells (A2058)

Feyzmohamadi Khoramabadi, Mohadese; Nemati, Ali; Homayouni Tabrizi, Masoud

doi:10.48307/FMSJ.2024.28.3.261

[Home ] [Archive]

[ فارسی ]

Main Menu

Home

Journal Information

Indexing Sources

Guide for Authors

Online Submission

Ethics

Articles archive

For Reviewers

Contact us

Basic and Clinical Biochemistry and Nutrition

DOAJ

CINAHL

EBSCO

IMEMR

ISC

Search in website

Receive site information

enamad

Volume 28, Issue 3 (August-September 2024)

Feyz Med Sci J 2024, 28(3): 261-270

Back to browse issues page

Evaluation of the toxicity and anti-angiogenic effects of beta-cyclodextrin complex loaded with thymol in melanoma skin cancer cells (A2058)

Mohadese Feyzmohamadi Khoramabadi

, Ali Nemati ^*

, Masoud Homayouni Tabrizi

Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran , neamati.ali@gmail.com

Abstract: (485 Views)

Background and Aim: In drug delivery, the formation of cyclodextrin complexes is a widely used strategy to overcome biopharmaceutical challenges associated with various active pharmaceutical ingredients, such as poor water solubility, initial instability, and low bioavailability. Given the anti-cancer properties of thymol, this study aimed to evaluate the effects of thymol-loaded nanoparticles in a beta-cyclodextrin complex and to assess their anti-cancer effects in melanoma skin cancer cells (A2058) by examining the expression of the VEGF and VEGFR genes.
Methods: The synthesized nanoparticles were characterized using various methods, including zeta potential analysis, ultraviolet-visible spectroscopy (UV-Vis), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and scanning electron microscopy (SEM). To determine the cytotoxicity of the synthesized nanocomplex, the MTT assay was performed with β-CD-Thymol nanoparticle concentrations ranging from 62.5 to 500 μg/ml. The Chorioallantoic Membrane (CAM) assay was conducted to evaluate the cytotoxicity of the synthesized β-CD-Thymol nanoparticles in the context of angiogenesis. Finally, the expression levels of genes involved in angiogenesis (VEGF and VEGFR) were analyzed using real-time PCR.
Results: Dynamic light scattering analysis revealed that the mean size of the nanoparticles was 116.20 nm, with a zeta potential of -21.64 mV. FTIR studies indicated the presence of several biologically active functional groups in the synthesized nanoparticles. Additionally, the anti-cancer effects and inhibitory role of the β-CD-Thymol complex were confirmed by a significant reduction in the expression of angiogenesis-related genes (VEGF and VEGFR) in A2058 cells treated with the β-CD-Thymol nanoparticle complex (P < 0.001). The results from the CAM assay further supported these findings.
Conclusion: The findings of this study demonstrated a significant decrease in the expression of genes involved in angiogenesis, specifically VEGF and VEGFR, indicating that the β-CD-Thymol complex effectively inhibits angiogenesis in the A2058 skin cancer cell line. Overall, in addition to inhibiting the formation of new blood vessels, the β-CD-Thymol nanostructure shows promise as an anti-angiogenic agent by modulating the expression of VEGF and VEGFR genes.

Keywords: Thymol, Beta-Cyclodextrin, Melanoma, VEGF, VEGFR

Full-Text [PDF 900 kb] (184 Downloads)

Type of Study: Research | Subject: General
Received: 2023/09/2 | Revised: 2024/09/24 | Accepted: 2024/07/24 | Published: 2024/08/31

References

1. Kim JE, Chung BY, Sim CY, Park AY, Lee JS, Whang KU, et al. Clinicopathologic features and prognostic factors of primary cutaneous melanoma: A multicenter study in Korea. J Korean Med Sci. 2019; 34(16): e126. doi: 10.3346/jkms.2019.34.e126.

2. Shi J, Kantoff PW, Wooster R, Farokhzad OCJNrc. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1):20-37. doi: 10.1038/nrc.2016.108. Epub 2016 Nov 11.

3. Tahergorabi Z, Khazaei MJIjobms. A review on angiogenesis and its assays. Iran J Basic Med Sci. 2012; 15(6):1110-26.

4. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast cancer (Tokyo, Japan). Breast Cancer. 2007; 14(2):163-73. doi: 10.2325/jbcs.968.

5. Nakatsu MN, Sainson RC, Pérez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, et al. VEGF121 and VEGF165 regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest. 2003; 83(12): 1873-85. doi: 10.1097/01.lab.0000107160.81875.33.

6. Ellis LM, Hicklin DJJNrc. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8): 579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.

7. Karthic A, Roy A, Lakkakula J, Alghamdi S, Shakoori A, Babalghith AO, et al. Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review. Front Cell Dev Biol. 2022; 10: 984311.

8. Elbe H, Yigitturk G, Cavusoglu T, Uyanikgil Y, Ozturk F. Apoptotic effects of thymol, a novel monoterpene phenol, on different types of cancer. Bratisl Lek Listy. 2020; 121(2): 122-8.

9. Shabestarian H, Homayouni M, Movahedi M, Neamati A, Sharifnia F. Green Synthesis and Comparison of Biological Properties of Ag-NPs as a Metal Nanoparticle with ZnO-NPs as a Metal Oxide Nanoparticle and their Applications2022.

10. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clin Diagnosis Management Breast Cancer. J Nucl Med. 2016; 57 Suppl 1:9s-16s.

11. Viac J, Schmitt D, Claudy AJCl. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett. 1998; 125(1-2): 35-8.

12. Aydın E, Turkez H, Tasdemir S, Hacımuftuoglu FJCNSAiMC. Anticancer, antioxidant and cytotoxic potential of thymol in vitro brain tumor cell model. Cent Nerv Syst Agents Med Chem. 2017; 17(2): 116-22.doi: 10.2174/1871524916666160823121854.2017;

13. Stryker ZI, Rajabi M, Davis PJ, Mousa SA. Evaluation of Angiogenesis Assays. Biomedicines. 2019; 7(2): 37. doi: 10.3390/biomedicines7020037.

14. Abed RM. Cytotoxic, cytogenetics and immunomodulatory effects of thymol from Thymus vulgaris on cancer and normal cell lines in vitro and in vivo. Al-Mustansiriyah J Sci. 2011; 22(4): 41-53.

Send email to the article author

Add your comments about this article

‎ 10.48307/FMSJ.2024.28.3.261

Mendeley

Zotero

RefWorks

Feyzmohamadi Khoramabadi M, Nemati A, Homayouni Tabrizi M. Evaluation of the toxicity and anti-angiogenic effects of beta-cyclodextrin complex loaded with thymol in melanoma skin cancer cells (A2058). Feyz Med Sci J 2024; 28 (3) :261-270
URL: http://feyz.kaums.ac.ir/article-1-4971-en.html

This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.

Volume 28, Issue 3 (August-September 2024)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 46 queries by YEKTAWEB 4660